.svg){kind=small}
Authors: Pierpaolo Pellicori MD, John G.F. Cleland MD, PhD, Maria Borentain MD, Jorg Taubel MD, Fraser Graham MB ChB, Javed Khan MB ChB, Dario Bruzzese PhD, Paul Kessler MD, John J.V. McMurray MD, Adriaan A. Voors MD, PhD, Christopher M. O'Connor MD, John R. Teerlink MD, G. Michael Felker MD, MHSIn a recent publication in the European Journal of Heart Failure (November 2023), the impact of cimlanod, a vasodilator, on diuretic response in congestive heart failure patients is explored. Download
-min.jpg)
.jpg)
Latest news
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read moreA first of a kind trial in the fight against malaria
June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read moreEvents
AHA Hypertension Scientific Sessions 2024
5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event
